Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study

Effect of Helicobacter Pylori Eradication on Symptoms and Quality of Life of Irritable Bowel Syndrome: A Prospective Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04512898

Enrollment

100

Registered

2020-08-14

Start date

2020-08-10

Completion date

2020-11-10

Last updated

2020-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

H. Pylori is frequently observed in patients with irritable bowel syndrome(IBS). However, the effect of H. pylori eradication on IBS is not clear.

Detailed description

Patients with IBS symptoms using Rome IV criteria will be included. Testing for H. pylori will be done. Patients with H. pylori will receive triple therapy and followed after two weeks for eradication and assessment of IBS symptoms.

Interventions

DRUGTriple therapy for H.pylori

Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Patients with IBS and have H. pylori

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients newly diagnosed with IBS and H.pylori

Exclusion criteria

* Patients received previous treatment of H.pylori * Patients receiving treatment for IBS.

Design outcomes

Primary

Measure	Time frame	Description
Questionnaire for Rome IV criteria	2 weeks	Symptoms of IBS

Secondary

Measure	Time frame	Description
Quality of life questionnaire	2 weeks	Quality of life.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026